Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | KDM1A | O60341 | 4/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.57 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 3/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13389686 | 1.00 | NPC1 (0.71) | NPC1RAB9AKDM1AHDAC3HDAC11 | |
| SCHEMBL13389585 | 0.85 | HDAC3 (0.53) | NPC1RAB9AKDM1AHDAC3HDAC11 | |
| SCHEMBL3302470 | 0.85 | HDAC3 (0.53) | NPC1RAB9AKDM1AHDAC3HDAC11 | |
| SCHEMBL14113705 | 0.85 | HDAC3 (0.53) | NPC1RAB9AKDM1AHDAC3HDAC11 | |
| SCHEMBL2565768 | 0.84 | HDAC3 (0.73) | NPC1RAB9AKDM1AHDAC3HDAC11 | |
| SCHEMBL3278764 | 0.84 | NPC1 (1.00) | NPC1RAB9AKDM1ADEGS1SMN1; SMN2 | |
| SCHEMBL3300701 | 0.84 | DEGS1 (0.58) | NPC1RAB9AHDAC3HDAC11HDAC8 | |
| SCHEMBL3300711 | 0.84 | DEGS1 (0.58) | NPC1RAB9AHDAC3HDAC11HDAC8 | |
| SCHEMBL14113698 | 0.84 | DEGS1 (0.58) | NPC1RAB9AHDAC3HDAC11HDAC8 | |
| SCHEMBL15021866 | 0.81 | HDAC4 (0.51) | KDM1APTPN1DEGS1POLBSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| WO-2008099221-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | CPS1, GOT2, GPR119 | NPC1 630/4885RAB9A 1908/4885KDM1A 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.